Bazemore Robert B — SEC insider filings

SEC reporting owner CIK 1620152. 24 insider filings on record with FilingPulse; latest filed 2026-10-16.

Transaction summary — filings shown

Covers all 24 filings on record, filed 2021-01-27 to 2026-10-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Epizyme, Inc. (EPZM)President & CEO, Director4—3 legs · 20,287 sh · $193,9292
Nuvation Bio Inc. (NUVB)Director91 leg · 5,000 sh · $49,900—9
Akari Therapeutics Plc (AKTX)Director5——18
ARDELYX, INC. (ARDX)Director6——8

Insider filings — Bazemore Robert B

FiledFormIssuerReported transactionsSource
2026-10-164Akari Therapeutics Plc (AKTX)Grant/award (A): 13,100 @ $7.90 · Grant/award (A): 4,677 @ $7.90 · Option exercise (M): 773 @ $0.00 · Option exercise (M): 3,093 @ $0.00 · Grant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 · +2 moreEDGAR
2026-06-184ARDELYX, INC. (ARDX)Grant/award (A): 26,455 @ $0 · Grant/award (A): 39,715 (derivative) @ $0EDGAR
2026-05-264Nuvation Bio Inc. (NUVB)Grant/award (A): 123,397 (derivative) @ $0EDGAR
2025-12-184Akari Therapeutics Plc (AKTX)Purchase (P): 123,731 (derivative) · Purchase (P): 123,731 (derivative) @ $0.40 · Purchase (P): 30,932 (derivative) · Purchase (P): 30,932 (derivative) @ $0.40EDGAR
2025-06-234ARDELYX, INC. (ARDX)Grant/award (A): 41,551 @ $0 · Grant/award (A): 54,059 (derivative) @ $0EDGAR
2025-05-234Nuvation Bio Inc. (NUVB)Grant/award (A): 292,983 (derivative) @ $0EDGAR
2025-03-244Akari Therapeutics Plc (AKTX)Grant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 225,000 (derivative) @ $0EDGAR
2025-03-104Akari Therapeutics Plc (AKTX)Grant/award (A): 44,642 @ $1.12 · Grant/award (A): 44,642 (derivative) @ $1.12 · Grant/award (A): 44,642 (derivative) @ $1.12EDGAR
2024-09-184Akari Therapeutics Plc (AKTX)Grant/award (A): 5,000,000 (derivative) @ $0EDGAR
2024-09-054Nuvation Bio Inc. (NUVB)Grant/award (A): 200,801 (derivative) @ $0EDGAR
2024-06-174ARDELYX, INC. (ARDX)Grant/award (A): 40,243 (derivative) @ $0EDGAR
2023-06-164ARDELYX, INC. (ARDX)Grant/award (A): 49,237 (derivative) @ $0EDGAR
2023-05-174Nuvation Bio Inc. (NUVB)Grant/award (A): 366,744 (derivative) @ $0EDGAR
2022-06-284/ANuvation Bio Inc. (NUVB)Grant/award (A): 140,713 (derivative) @ $0EDGAR
2022-06-174ARDELYX, INC. (ARDX)Grant/award (A): 100,000 (derivative) @ $0EDGAR
2022-05-184Nuvation Bio Inc. (NUVB)Grant/award (A): 118,784 (derivative) @ $0EDGAR
2021-11-024Nuvation Bio Inc. (NUVB)Grant/award (A): 45,229 (derivative) @ $0EDGAR
2021-06-214ARDELYX, INC. (ARDX)Grant/award (A): 32,765 (derivative) @ $0EDGAR
2021-04-014Nuvation Bio Inc. (NUVB)Purchase (P): 5,000 @ $9.98EDGAR
2021-03-294Epizyme, Inc. (EPZM)Sale (S): 10,328 @ $7.85EDGAR
2021-02-124Nuvation Bio Inc. (NUVB)Grant/award (A): 51,703 (derivative) · Grant/award (A): 187,658 (derivative)EDGAR
2021-02-054Epizyme, Inc. (EPZM)Sale (S): 3,890 @ $11.21EDGAR
2021-02-024Epizyme, Inc. (EPZM)Grant/award (A): 87,500 @ $0 · Grant/award (A): 417,443 (derivative) @ $0EDGAR
2021-01-274Epizyme, Inc. (EPZM)Sale (S): 6,069 @ $11.41EDGAR

FilingPulse's Form 4 archive currently extends back to 2021-01-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1620152 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs